Xpert Xpress CoV-2/Flu plus
Cepheid · Decision date Oct 22, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision for the Xpert Xpress CoV-2/Flu plus, 510(k) number K263333, on October 22, 2026, with the application received September 22, 2026. The applicant is Cepheid of Sunnyvale, California. The device falls under regulation 866.3981, classification product code QOF with subsequent product code OOI, in the Microbiology specialty and review panel. A SESE decision is a 510(k) clearance, not a PMA approval.
The submitted document states the test runs on the GeneXpert Xpress System, described as a GeneXpert IV instrument that performs sample preparation, nucleic acid amplification and real-time fluorescent signal detection, together with a GeneXpert Hub with preloaded GeneXpert Xpress software for running tests and viewing results. The public record lists no summary statement, and the provided material does not give clinical performance data, indications wording or the specific changes relative to a prior cleared version.
The record also shows the review was not by a third party, was not a combination product, and had no authorized predetermined change control plan. Whether this filing represents a modification of an earlier Cepheid clearance is not established by the public information.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Microbiology
- Decision date
- Oct 22, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K263333
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Cepheid
- Product code
- QOF
- Decision code
- SESE
- Decision date
- Oct 22, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents.
FDA decision timeline
K263333 received
Application receipt date recorded by FDA.
K263333 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code QOF
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| GenMark Diagnostics, Inc. | 510(k) clearance | Oct 30, 2026 | FDA | |
Xpert Xpress CoV-2/Flu plusK263120 | Cepheid | 510(k) clearance | Oct 2, 2026 | FDA |
Xpert Respiratory PanelK261336 | Cepheid | 510(k) clearance | Sep 25, 2026 | FDA |
| Biofire Diagnostics | 510(k) clearance | Sep 22, 2026 | FDA | |
| Baebies, Inc. | 510(k) clearance | Sep 11, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Cepheid
- Headquarters
- Not reported
- Brand website
- cepheid.com
- FDA applicant address
- Sunnyvale, CA
Sources and methodology
- Original FDA record: K263333
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

